Global Hepatitis B Therapeutics Markets, 2022-2026: A Strong Pipeline and Increasing Awareness and Screening Programs of HBV Diagnostic Tests will Lead to Sizable Demand – ResearchAndMarkets.com

Global Hepatitis B Therapeutics Markets, 2022-2026: A Strong Pipeline and Increasing Awareness and Screening Programs of HBV Diagnostic Tests will Lead to Sizable Demand – ResearchAndMarkets.com




Global Hepatitis B Therapeutics Markets, 2022-2026: A Strong Pipeline and Increasing Awareness and Screening Programs of HBV Diagnostic Tests will Lead to Sizable Demand – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global Hepatitis B Therapeutics Market 2022-2026” report has been added to ResearchAndMarkets.com’s offering.

The Hepatitis B therapeutics market is poised to grow by $471.49 mn during 2022-2026 progressing at a CAGR of 3.29%

The market is driven by the increasing prevalence of hepatitis B in infants, growing initiatives to increase awareness about hepatitis B, and growing demand for molecular diagnostics of HBV.

This study identifies the new technological advancements as one of the prime reasons driving the hepatitis b therapeutics market growth during the next few years. Also, a strong pipeline, and increasing awareness and screening programs of HBV diagnostic tests will lead to sizable demand in the market.

The report on the hepatitis b therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors. The report offers an up-to-date analysis of the current global market scenario, the latest trends and drivers, and the overall market environment. The hepatitis b therapeutics market analysis includes application segment and geographic landscape.

The publisher’s robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading hepatitis b therapeutics market vendors that include ABIVAX, Biotest AG, Bristol Myers Squibb Co., CASI Pharmaceuticals Inc., Cipla Ltd., Dynavax Technologies Corp., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Hetero Healthcare Ltd., Johnson and Johnson, Merck and Co. Inc., Novartis AG, Sanofi SA, Teva Pharmaceutical Industries Ltd., Viatris Inc., and Emergent BioSolutions Inc..

Also, the hepatitis b therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

Key Topics Covered:

1 Executive Summary

1.1 Market overview

2 Market Landscape

2.1 Market ecosystem

3 Market Sizing

3.1 Market definition

3.2 Market segment analysis

3.3 Market size 2021

3.4 Market outlook: Forecast for 2021-2026

4 Five Forces Analysis

4.1 Five forces summary

4.2 Bargaining power of buyers

4.3 Bargaining power of suppliers

4.4 Threat of new entrants

4.5 Threat of substitutes

4.6 Threat of rivalry

4.7 Market condition

5 Market Segmentation by Application

5.1 Market segments

5.2 Comparison by Application

5.3 Drugs – Market size and forecast 2021-2026

5.4 Vaccines – Market size and forecast 2021-2026

5.5 Market opportunity by Application

6 Customer Landscape

6.1 Customer landscape overview

7 Geographic Landscape

7.1 Geographic segmentation

7.2 Geographic comparison

8 Drivers, Challenges, and Trends

8.1 Market drivers

8.2 Market challenges

8.3 Impact of drivers and challenges

8.4 Market trends

9 Vendor Landscape

9.1 Overview

9.2 Vendor landscape

9.3 Landscape disruption

9.4 Industry risks

10 Vendor Analysis

10.1 Vendors covered

10.2 Market positioning of vendors

  • ABIVAX
  • Biotest AG
  • Bristol Myers Squibb Co.
  • CASI Pharmaceuticals Inc.
  • Cipla Ltd.
  • Dynavax Technologies Corp.
  • F. Hoffmann La Roche Ltd.
  • Gilead Sciences Inc.
  • GlaxoSmithKline Plc
  • Hetero Healthcare Ltd.
  • Johnson and Johnson
  • Merck and Co. Inc.
  • Novartis AG
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Emergent BioSolutions Inc.

For more information about this report visit https://www.researchandmarkets.com/r/qty563

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900